Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minaprine SCHEMBL49371 | 0.88 | ACHE (1.00) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10744195 | 0.88 | ACHE (0.78) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| Minaprine SCHEMBL124094 | 0.87 | CYP3A4 (1.00) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| Minaprine SCHEMBL124092 | 0.87 | CYP3A4 (1.00) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10748868 | 0.87 | ACHE (0.77) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| Minaprine SCHEMBL124093 | 0.86 | ACHE (0.95) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10746423 | 0.83 | CYP3A4 (0.74) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10958697 | 0.82 | ACHE (0.72) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1753025 | 0.79 | ACHE (0.64) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10958038 | 0.78 | ACHE (0.69) | ACHELMNACYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| CN-101277684-A | Microparticles for the modified release of at least one active principle and oral pharmaceutical forms containing them | FLAMEL TECH SA (FR) | 2008-10-01 | — | — | CN | claimed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4704983-A2 | TREATMENT OF MEMORY LOSS WITH PHOSPHODIESTERASE INHIBITORS | Cyrano Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260041690-A1 | Treatment of Memory Loss with Phosphodiesterase Inhibitors | CYRANO THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041690-A1 | Treatment of Memory Loss with Phosphodiesterase Inhibitors | PDE2A, PDE4A, PDE3A | ACHE 324/4885LMNA 3182/4885CYP3A4 3936/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | ACHE 2021/4885LMNA 2554/4885CYP3A4 975/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | ACHE 49/4885LMNA 2584/4885CYP3A4 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.